Search

Fungi are a diverse group of organisms that play an essential role in the biosphere. They have a unique ability to produce a vast array of secondary metabolites, including enzymes that have important applications in various industries. Fungal enzymes have been utilized in many fields, such as food processing, textile, paper, and pulp industries, to name a few. In recent years, there has been growing interest in the use of fungal enzymes in the synthesis of pharmaceutical compounds due to their scalability, high catalytic activity, relatively low cost, and ability to catalyze a wide range of chemical reactions under mild reaction conditions making the overall process greener and sustainable. Fungi produce a variety of enzymes such as oxidoreductases, transferases, and hydrolases which can be used in the synthesis of specific compounds with required chemo-, regio-, and stereoselectivity. This paper discusses the role of fungal enzymes in the synthesis of various drugs, active pharmaceutical ingredients (API), and drug intermediates and their applications in the pharmaceutical industry. [ABSTRACT FROM AUTHOR]

New candidates of imidazo[1,2‐a]pyridine were designed by combining 2‐amino pyridine, TOSMIC and various assorted aldehydes to explore their antioxidant and antifungal potential. The design of these derivatives was based on utilizing the antifungal potential of azoles and TOSMIC moiety. These derivatives were synthesized by adopting multi‐component reaction methodology, as it serves as a rapid and efficient tool to target structurally diverse heterocyclic compounds in quantitative yield. The resulting imidazo[1,2‐a]pyridine derivatives were structurally verified by 1HNMR, 13CNMR, HRMS, and HPLC. The compounds were analyzed for their antioxidant and fluorescent properties and it was observed that compound 15 depicted highest potential. The compounds were evaluated for their antifungal potential to highlight their medical application in the area of Invasive Fungal Infections (IFI). Compound 12 gave the highest antifungal inhibition against Aspergillus fumigatus 3007 and Candida albicans 3018. To elucidate the antifungal mechanism, confocal images of treated fungi were analyzed, which depicted porous nature of fungal membrane. Estimation of fungal membrane sterols by UPLC indicated decrease in ergosterol component of fungal membrane. In silico studies further corroborated with the in vitro results as docking studies depicted interaction of synthesized heterocyclic compounds with amino acids present in the active site of target enzyme (lanosterol 14 alpha demethylase). Absorption, distribution, metabolism, and excretion (ADME) analysis was indicative of drug‐likeliness of the synthesized compounds. [ABSTRACT FROM AUTHOR]